Mula 23: Here is the complete DSM-5 classification of Sleep-Wake Disorders, with each disorder formatted exactly like the Insomnia Disorder lecture you approved. Each disorder includes the same structure: definition, diagnostic criteria (Criterion A through H or equivalent), specifiers, and key features. The case scenarios are removed. Easy to copy and paste. --- Insomnia Disorder Definition – What Is Insomnia Disorder? Insomnia Disorder is not just one bad night of sleep. It is a clinical condition defined by dissatisfaction with sleep quantity or quality despite having a proper opportunity to sleep. Three main complaints define it: 1. Difficulty falling asleep (lying awake for 30+ minutes) 2. Difficulty staying asleep (waking up multiple times, trouble getting back to sleep) 3. Early morning awakening (waking up 30+ minutes before desired time, unable to go back to sleep) Key point: The patient must have adequate opportunity – meaning a bed, a quiet room, enough time. If a person chooses to sleep only 4 hours because of work, that is not insomnia disorder. --- Types of Insomnia (Based on Complaint) Type 1: Sleep-Onset Insomnia - Trouble falling asleep at bedtime Type 2: Sleep-Maintenance Insomnia - Waking up multiple times during the night Type 3: Early-Morning Awakening Insomnia - Waking too early and cannot go back to sleep Note: A patient can have one or more types. --- Epidemiology – Who Gets It? Females are more affected than males (approximately 1.5 to 2 times higher) Older adults are more affected than younger adults Patients with psychiatric disorders – up to 50-80% of depressed patients have insomnia Insomnia is one of the most common sleep disorders in the general population. --- Risk Factors (Four Categories) Psychological: · Stress · Anxiety · Depression · Rumination Environmental: · Shift work · Noise · Irregular sleep schedules Behavioral: · Excess caffeine · Screen exposure before bed · Daytime naps Medical: · Chronic pain · Neurological disease (Parkinson's) · Respiratory disease (COPD, asthma) Notice: Many of these are modifiable. That is why behavioral interventions work well. --- Pathophysiology – What Is Happening in the Brain? The leading theory: Hyperarousal Key features: · Increased stress hormones (cortisol, adrenaline) – even at night · Increased brain activity during sleep – EEG shows faster frequencies, less slow-wave sleep · The brain is stuck in an alert state, unable to power down Clinical takeaway: Insomnia is not a lack of sleep drive – it is an excess of wake drive. --- Clinical Features (Day vs. Night) Nighttime Symptoms: · Difficulty sleeping · Frequent awakenings · Restless, light, non-restorative sleep Daytime Symptoms (The Next-Day Cost): · Fatigue (not necessarily sleepiness) · Irritability · Poor concentration · Mood disturbance (anxious or low mood) · Daytime sleepiness (less common but possible) Exam tip: Daytime symptoms are required for diagnosis. Insomnia without daytime impairment is not a disorder. --- DSM-5 Diagnostic Criteria (Part 1 of 2) Criterion A: The patient complains of at least one of: · A1. Difficulty initiating sleep (falling asleep) · A2. Difficulty maintaining sleep (staying asleep) · A3. Early-morning awakening (cannot return to sleep) Criterion B: The sleep disturbance causes clinically significant distress or impairment in: · Social functioning (relationships suffer) · Occupational functioning (job performance declines) · Educational functioning (grades drop) · Behavioral functioning (mood swings, irritability) Criterion C: Frequency – At least 3 nights per week Criterion D: Duration – At least 3 months Note: 3 nights per week for 3 months equals persistent insomnia. Less than 3 months but meeting other criteria equals episodic specifier. --- DSM-5 Diagnostic Criteria (Part 2 of 2) Criterion E: Occurs despite adequate opportunity for sleep (not because of shift work or voluntary sleep deprivation) Criterion F: Not better explained by another sleep disorder, such as: · Narcolepsy · Obstructive Sleep Apnea Hypopnea (OSA) · Circadian rhythm disorders · Parasomnias (sleepwalking, night terrors) Criterion G: Not attributable to substances or medications, for example: · Caffeine · Cocaine · Amphetamines · Steroids · Certain antidepressants Criterion H: Coexisting mental disorders or medical conditions do not adequately explain the insomnia Example: Depression causes both low mood and insomnia. If low mood is the main problem, diagnose depression first. But if insomnia persists after treating depression, then diagnose insomnia disorder. Clinical pearl: Insomnia can be a symptom of another disorder or an independent disorder. Criterion H helps you decide. --- DSM-5 Specifiers (Subtypes) These specifiers describe what accompanies the insomnia. Specifier 1: With Non-Sleep Disorder Mental Comorbidity · Occurs with psychiatric disorders like Major Depressive Disorder or Generalized Anxiety Disorder Specifier 2: With Other Medical Comorbidity · Occurs with medical illnesses like asthma (wakes from coughing), arthritis (wakes from pain), chronic pain conditions Specifier 3: With Other Sleep Disorder · Insomnia plus another sleep disorder, e.g., Restless Legs Syndrome Think of these as co-occurring conditions – not caused by but alongside. --- Course Specifiers (Time Course) Episodic: · Symptoms last 1 to 3 months Persistent: · Symptoms last more than 3 months Recurrent: · Two or more episodes within one year These specifiers describe the longitudinal course of the disorder. --- Differential Diagnosis (What Else Could It Be?) Hypersomnolence Disorder: · Key distinction: Main complaint is excessive sleepiness, not difficulty sleeping Narcolepsy: · Key distinction: Sleep attacks, cataplexy, sleep paralysis Obstructive Sleep Apnea: · Key distinction: Sleep fragmentation from airway obstruction; snoring, apneas observed Circadian Rhythm Disorders: · Key distinction: Biological clock mismatch (e.g., delayed sleep phase) Major Depressive Disorder: · Key distinction: Mood symptoms predominate; insomnia improves when mood improves Always rule out sleep apnea before treating insomnia – especially in snorers or overweight patients. --- Comorbidity (Frequently Associated Conditions) Insomnia rarely travels alone. Common comorbidities include: · Depression (bidirectional – each worsens the other) · Anxiety disorders (especially GAD and panic disorder) · Substance use disorders (alcohol, sedatives) · Medical illnesses (hypertension, diabetes, chronic pain) Principle: Treat both insomnia and the comorbidity simultaneously for best outcomes. --- Functional Consequences Untreated insomnia leads to: · Poor work performance (errors, absenteeism) · Academic impairment (failing exams) · Increased accidents (motor vehicle, workplace) · Reduced quality of life (comparable to chronic pain or depression) Insomnia is not just a nighttime problem – it affects every aspect of daily living. --- Treatment – Non-Pharmacological (First-Line) First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I) – the gold standard Components of CBT-I: 1. Sleep hygiene 2. Stimulus control – bed only for sleep and sex; get up if not sleeping after 20-30 minutes 3. Sleep restriction – limit time in bed to actual sleep time, then gradually increase 4. Relaxation therapy – progressive muscle relaxation, mindfulness, deep breathing CBT-I is as effective as medication long-term, with no side effects and lasting benefits. --- Treatment – Sleep Hygiene and Medications Sleep Hygiene (Basic Advice): · Maintain regular sleep schedule (same wake time every day, even weekends) · Avoid caffeine 6-8 hours before bed · Reduce screen exposure 1 hour before bed (blue light suppresses melatonin) · Exercise regularly (but not 2-3 hours before bed) · Avoid large meals, alcohol before bed Pharmacological Treatment (Second-line or Adjunctive): Class: Benzodiazepines Examples: Temazepam, lorazepam Caution: Dependence, tolerance, falls in elderly Class: Non-benzodiazepine hypnotics Examples: Zolpidem (Ambien), eszopiclone Caution: Daytime sedation, complex sleep behaviors (sleep-driving) Class: Melatonin agonists Examples: Ramelteon, low-dose melatonin Caution: Fewer dependence risks, less potent Rule: Medications are for short-term use (weeks, not months). Never first-line unless CBT-I is unavailable or patient refuses. --- Prognosis Excellent with CBT-I: · 70-80% of patients improve significantly Good with proper sleep hygiene and treatment of underlying conditions Poor if untreated: · Chronic insomnia persists for years · High risk of developing depression or anxiety Key quote: Once insomnia becomes chronic, it rarely goes away on its own. It must be treated. --- Final Summary of Key Points 1. Insomnia Disorder requires dissatisfaction with sleep quantity or quality despite adequate opportunity 2. Three types: sleep-onset, sleep-maintenance, early-morning awakening 3. DSM-5 requires 3 nights per week for at least 3 months with daytime impairment 4. First-line treatment is CBT-I, not medication 5. Prognosis is excellent with proper treatment 6. Always rule out other sleep disorders like obstructive sleep apnea --- Hypersomnolence Disorder Definition – What Is Hypersomnolence Disorder? Hypersomnolence Disorder is characterized by excessive sleepiness despite a primary sleep period lasting at least 7 hours. The patient has difficulty maintaining wakefulness and may fall asleep repeatedly during the day. Key distinction from insomnia: The main complaint is excessive sleepiness, not difficulty falling or staying asleep at night. --- Types of Symptoms (Three Possible Presentations) Presentation 1: Recurrent periods of sleep or lapses into sleep within the same day Presentation 2: A prolonged main sleep episode of more than 9 hours per day that is non-restorative (not refreshing) Presentation 3: Difficulty being fully awake after abrupt awakening Note: The patient must have at least one of these three. --- Epidemiology – Who Gets It? Prevalence: Approximately 1% of the population Onset: Typically in late adolescence or early adulthood (ages 17-24) Chronicity: Usually a lifelong condition with persistent symptoms Gender: Slightly more common in males than females --- Risk Factors Genetic: · Family history of hypersomnolence · Possible genetic predisposition (specific genes not yet identified) Environmental: · Sleep deprivation (can unmask or worsen symptoms) · Viral illnesses (some cases begin after infections like mononucleosis) Medical: · Head trauma · Neurological conditions (Parkinson's, multiple sclerosis) · Genetic disorders (myotonic dystrophy) Psychological: · Depression (must rule out that depression is causing the sleepiness) --- Pathophysiology – What Is Happening in the Brain? Understanding is limited compared to narcolepsy. Possible mechanisms include: · Central nervous system hyperexcitability during sleep · Impaired arousal systems in the brainstem · Possible dysfunction of hypocretin system (but not as severe as narcolepsy type 1) · Altered GABAergic transmission Key point: Unlike narcolepsy, cataplexy is absent, and hypocretin levels are normal. --- Clinical Features Nighttime Features: · Prolonged sleep episodes (9+ hours) · Difficulty waking up in the morning (sleep drunkenness) · Frequent and long naps · Very deep sleep with vivid dreams Daytime Features: · Excessive sleepiness (falling asleep at work, school, while driving) · Difficulty maintaining alertness · Cognitive slowing (brain fog) · Automatic behaviors (performing tasks without memory) Key feature: Naps are typically long (over 1 hour) and are not refreshing. --- DSM-5 Diagnostic Criteria (Part 1 of 2) Criterion A: Self-reported excessive sleepiness (hypersomnolence) despite a main sleep period lasting at least 7 hours, with at least one of the following symptoms: · (1) Recurrent periods of sleep or lapses into sleep within the same day · (2) A prolonged main sleep episode of more than 9 hours per day that is non-restorative · (3) Difficulty being fully awake after abrupt awakening Criterion B: Hypersomnolence occurs at least 3 times per week Criterion C: Present for at least 3 months --- DSM-5 Diagnostic Criteria (Part 2 of 2) Criterion D: Causes clinically significant distress or impairment in cognitive, social, occupational, or other functioning Criterion E: Not better explained by another sleep disorder (narcolepsy, breathing-related disorder, circadian rhythm disorder, parasomnia) Criterion F: Not attributable to substance effects (e.g., drugs, alcohol, medications) Criterion G: Coexisting mental or medical conditions do not adequately explain the hypersomnolence Example: Depression can cause hypersomnia. If low mood is the primary problem, treat depression first. If sleepiness persists after mood improves, then diagnose hypersomnolence disorder. --- Specifiers With Non-Sleep Disorder Mental Comorbidity: · Occurs with psychiatric disorders such as bipolar disorder or depression With Other Medical Comorbidity: · Occurs with medical illnesses such as Parkinson's disease or multiple sclerosis With Other Sleep Disorder: · Occurs with another sleep disorder such as obstructive sleep apnea or restless legs syndrome Course Specifiers: · Episodic: 1 to 3 months · Persistent: More than 3 months · Recurrent: Two or more episodes within one year --- Differential Diagnosis (What Else Could It Be?) Narcolepsy Type 1: · Key distinction: Cataplexy and hypocretin deficiency are present Narcolepsy Type 2: · Key distinction: Requires multiple sleep latency testing showing two or more sleep-onset REM periods Obstructive Sleep Apnea: · Key distinction: Snoring, apneas, oxygen desaturation on polysomnography Circadian Rhythm Disorder (Delayed Sleep Phase): · Key distinction: Sleepiness only when forced to wake early; normal alertness when sleeping on own schedule Major Depressive Disorder with Atypical Features: · Key distinction: Mood symptoms predominate; hypersomnia improves when mood improves Substance Use (Sedatives, Alcohol, Cannabis): · Key distinction: Sleepiness resolves with abstinence --- Comorbidity (Frequently Associated Conditions) Hypersomnolence disorder frequently co-occurs with: · Depression (especially atypical depression) · Bipolar disorder (during depressive episodes) · Anxiety disorders · Obstructive sleep apnea (after treatment failure) · Medical conditions: Parkinson's disease, multiple sclerosis, myotonic dystrophy Principle: Treat the comorbid condition first. If hypersomnia persists, then treat independently. --- Functional Consequences Untreated hypersomnolence leads to: · Poor academic performance (falling asleep in class, missing lectures) · Occupational impairment (tardiness, errors, job loss) · Driving accidents (falling asleep at the wheel) · Social isolation (difficulty staying awake during social activities) · Cognitive deficits (poor memory, slow processing speed) --- Treatment (Part 1 of 2 – Non-Pharmacological) First-Line Non-Pharmacological Interventions: 1. Sleep hygiene optimization · Regular sleep-wake schedule · Avoid sleep deprivation 2. Scheduled naps · Planned short naps after meals · But note: naps are typically not refreshing 3. Behavioral counseling · Avoidance of activities that worsen sleepiness (long driving, heavy machinery) · Safety planning 4. Treatment of underlying conditions · Sleep apnea treatment if present · Psychiatric treatment if mood disorder is primary --- Treatment (Part 2 of 2 – Pharmacological) Pharmacological Treatment (Used when non-pharmacological is insufficient): First-line medications: · Modafinil or armodafinil (wake-promoting agents, low abuse potential) Second-line medications: · Amphetamine derivatives (methylphenidate, dextroamphetamine) · Caution: High abuse potential, tolerance, cardiovascular effects Other agents (limited evidence): · Clarithromycin (experimental) · Flumazenil (for rare cases) Rule: Medication is not first-line. Start with behavioral interventions and treat comorbidities. Important note: No medications are FDA-approved specifically for hypersomnolence disorder (unlike narcolepsy). --- Prognosis Good with: · Proper diagnosis (excluding other causes) · Treatment of underlying conditions · Combination of behavioral and pharmacological treatment Poor if untreated: · Chronic symptoms persisting for decades · High risk of accidents and occupational disability · May worsen with age Key quote: Hypersomnolence disorder is often a chronic condition requiring long-term management, but many patients improve significantly with treatment. --- Final Summary of Key Points 1. Hypersomnolence Disorder involves excessive sleepiness despite 7+ hours of sleep 2. Three presentations: sleep lapses, prolonged non-restorative sleep, or difficulty waking 3. DSM-5 requires 3 times per week for at least 3 months 4. Key differential: narcolepsy (no cataplexy, normal hypocretin) 5. First-line: behavioral interventions and safety planning 6. Pharmacological: modafinil or stimulants if needed 7. Prognosis: chronic but manageable --- Narcolepsy Definition – What Is Narcolepsy? Narcolepsy is a chronic neurological disorder characterized by the brain's inability to regulate sleep-wake cycles normally. The core symptom is recurrent periods of an irrepressible need to sleep or lapses into sleep occurring within the same day. Key distinction from hypersomnolence disorder: Narcolepsy includes specific features such as cataplexy, hypocretin deficiency, and sleep-onset REM periods. --- Two Types of Narcolepsy Type 1 (With Cataplexy): · Cataplexy present (brief episodes of bilateral loss of muscle tone) · Hypocretin deficiency (low or absent cerebrospinal fluid hypocretin-1) · More severe and more specific diagnosis Type 2 (Without Cataplexy): · No cataplexy · Normal hypocretin levels · Requires polysomnography findings (sleep-onset REM periods) --- Epidemiology – Who Gets It? Prevalence: Approximately 0.02% to 0.05% of general population (1 in 2,000 to 1 in 5,000) Onset: Bimodal – peak in adolescence (ages 15-25) and smaller peak in middle age (ages 35-45) Gender: Males and females equally affected Genetic: Strong association with HLA-DQB1*06:02 (95-100% of Type 1 cases) --- Risk Factors Genetic: · HLA-DQB1*06:02 (strongest genetic risk factor) · Family history (increased risk but most cases are sporadic) Environmental triggers (for Type 1): · Upper respiratory infections (especially Streptococcus pyogenes) · H1N1 influenza infection or vaccination (Pandemrix vaccine associated with increased risk) · Other infections or immune stress Autoimmune hypothesis: Narcolepsy Type 1 is believed to be caused by autoimmune destruction of hypocretin-producing neurons in the hypothalamus. --- Pathophysiology – What Is Happening in the Brain? Type 1 (With Cataplexy): · Loss of hypocretin (orexin) producing neurons in the lateral hypothalamus · Hypocretin is a neuropeptide that promotes wakefulness and stabilizes transitions between sleep-wake states · Cerebrospinal fluid hypocretin-1 is undetectable or very low Type 2 (Without Cataplexy): · Partial hypocretin deficiency or normal levels · Exact mechanism less understood Consequence: Inability to maintain stable boundaries between wake, NREM sleep, and REM sleep. This leads to: · Intrusion of REM sleep into wakefulness (cataplexy, sleep paralysis, hallucinations) · Abrupt transitions from wake to REM sleep (sleep-onset REM periods) --- Clinical Features (The Narcolepsy Pentad) Not all patients have all five features. Feature 1: Excessive Daytime Sleepiness (required for diagnosis) · Irrepressible need to sleep or lapses into sleep within the same day · Occurs at least 3 times per week over the past 3 months · Naps are typically refreshing (unlike hypersomnolence disorder) Feature 2: Cataplexy (only in Type 1) · Brief episodes (seconds to minutes) of bilateral loss of muscle tone · Triggered by strong emotions (laughter, anger, surprise) · Consciousness remains intact during the episode · Can be partial (drooping eyelids, head drop) or complete (knees buckle, falls) Feature 3: Hypnagogic or Hypnopompic Hallucinations · Hypnagogic: occurring while falling asleep · Hypnopompic: occurring while waking up · Vivid, often frightening, dream-like experiences (feeling someone in the room, auditory voices) Feature 4: Sleep Paralysis · Temporary inability to move or speak while falling asleep or waking up · Consciousness is fully preserved · Typically lasts seconds to a few minutes · Often terrifying but not dangerous Feature 5: Disrupted Nighttime Sleep · Frequent awakenings, vivid nightmares, periodic limb movements · May be misdiagnosed as insomnia --- DSM-5 Diagnostic Criteria (Part 1 of 2) Criterion A: Recurrent periods of an irrepressible need to sleep or lapses into sleep occurring within the same day, at least 3 times per week over the past 3 months Criterion B: The presence of at least one of the following: · (1) Episodes of cataplexy (Type 1) · (2) Hypocretin deficiency (measured by cerebrospinal fluid hypocretin-1 level – less than or equal to 110 pg/mL or less than one-third of normal control values) · (3) Nocturnal polysomnography showing REM sleep latency of less than or equal to 15 minutes, OR Multiple Sleep Latency Test showing mean sleep latency of less than or equal to 8 minutes and two or more sleep-onset REM periods --- DSM-5 Diagnostic Criteria (Part 2 of 2) Criterion C: The hypersomnolence and/or cataplexy are not better explained by another sleep disorder, medication/substance, or medical/mental condition Note: For diagnosis of narcolepsy, polysomnography and Multiple Sleep Latency Testing are typically required (except when cataplexy and hypocretin deficiency are clearly present) --- Specifiers Specify if: · Narcolepsy Type 1 (with cataplexy or hypocretin deficiency) · Narcolepsy Type 2 (without cataplexy and with normal hypocretin, but polysomnography/MSLT findings present) Note: The DSM-5 does not use separate course specifiers for narcolepsy as it is usually a lifelong condition. --- Differential Diagnosis (What Else Could It Be?) Hypersomnolence Disorder: · Key distinction: No cataplexy, no sleep-onset REM periods, naps are long and not refreshing Obstructive Sleep Apnea: · Key distinction: Snoring, apneas, oxygen desaturation; cataplexy absent Idiopathic Hypersomnia (Hypersomnolence Disorder): · Key distinction: No sleep-onset REM periods, longer sleep episodes (10+ hours), no cataplexy Circadian Rhythm Disorders: · Key distinction: Sleepiness resolves when sleeping on desired schedule; no cataplexy or sleep-onset REM Seizures (Atonic seizures): · Key distinction: Loss of consciousness during episodes; not triggered by emotion; EEG abnormalities Syncope (fainting): · Key distinction: Loss of consciousness, autonomic changes, not triggered by positive emotions --- Comorbidity (Frequently Associated Conditions) Narcolepsy frequently co-occurs with: · Depression (up to 30-50% of patients) · Anxiety disorders · Obesity (especially in Type 1 due to hypocretin's role in appetite regulation) · Obstructive sleep apnea (can coexist) · REM sleep behavior disorder · Periodic limb movement disorder Principle: Comorbid conditions must be treated simultaneously. Depression can worsen daytime sleepiness. --- Functional Consequences Untreated narcolepsy leads to: · Severe occupational disability (unable to maintain regular work schedule) · Academic failure (falling asleep in class, poor concentration) · Driving accidents (sudden sleep attacks while driving) · Social impairment (cataplexy triggered by laughter or excitement may cause avoidance of social situations) · Relationship difficulties (irritability, sleep paralysis misunderstood by partners) · Reduced quality of life (comparable to epilepsy or severe depression) --- Treatment (Part 1 of 2 – Non-Pharmacological) First-Line Non-Pharmacological Interventions: 1. Scheduled naps · Two to three short naps (15-20 minutes) per day · Particularly helpful for excessive daytime sleepiness 2. Sleep hygiene · Regular sleep-wake schedule · Adequate nighttime sleep (7-8 hours) 3. Safety counseling · Avoid driving during peak sleepiness · Discuss workplace accommodations (flexible hours, nap breaks) 4. Psychological support · Support groups (Narcolepsy Network) · Cognitive behavioral therapy for coping with chronic illness 5. Avoidance of triggers for cataplexy (for Type 1) · Recognize and manage emotional triggers when possible --- Treatment (Part 2 of 2 – Pharmacological) Pharmacological Treatment (Often necessary, unlike insomnia): For Excessive Daytime Sleepiness: · First-line: Modafinil or armodafinil (wake-promoting, low abuse potential) · Second-line: Amphetamine derivatives (methylphenidate, dextroamphetamine) – effective but higher abuse potential · Newer options: Solriamfetol, pitolisant (histamine-3 receptor antagonist) For Cataplexy (Type 1 only): · First-line: Venlafaxine (SNRI), fluoxetine (SSRI), or clomipramine (tricyclic) · Second-line: Sodium oxybate (GHB) – highly effective but tightly regulated · Newer: Pitolisant (also treats sleepiness and cataplexy) For Disrupted Nighttime Sleep: · Sodium oxybate (treats both cataplexy and nighttime sleep disruption) · Low-dose sedating antidepressants Rule: Treatment is typically lifelong. Medications are combined with behavioral interventions. --- Prognosis Good with: · Early diagnosis and treatment · Combination medication and behavioral management · Workplace and academic accommodations Poor if untreated: · Severe disability · High accident rates · Social isolation · Depression Key quote: Narcolepsy is a lifelong condition, but most patients can achieve significant symptom control and functional independence with proper treatment. --- Final Summary of Key Points 1. Narcolepsy causes irrepressible need to sleep within the same day 2. Two types: Type 1 (with cataplexy or hypocretin deficiency) and Type 2 (without) 3. Classic pentad: daytime sleepiness, cataplexy, hallucinations, sleep paralysis, disrupted nighttime sleep 4. Type 1 is caused by autoimmune loss of hypocretin neurons 5. Diagnosis requires polysomnography and Multiple Sleep Latency Test (except when cataplexy and hypocretin deficiency are clear) 6. Treatment includes scheduled naps, modafinil for sleepiness, and antidepressants or sodium oxybate for cataplexy 7. Prognosis is good with treatment, but condition is lifelong --- Breathing-Related Sleep Disorders (Overview) Definition – What Are Breathing-Related Sleep Disorders? Breathing-Related Sleep Disorders are sleep disorders caused by abnormal respiration during sleep. The DSM-5 classifies three distinct types based on the mechanism of breathing disruption. All three types lead to: · Sleep fragmentation · Excessive daytime sleepiness · Cardiovascular and metabolic consequences --- Three Types of Breathing-Related Sleep Disorders Type 1: Obstructive Sleep Apnea Hypopnea (OSA) · Most common type · Caused by upper airway collapse during sleep · Respiratory effort is present but airflow is blocked Type 2: Central Sleep Apnea · Caused by lack of respiratory effort from brainstem dysfunction · Airway is open but breathing stops because the brain does not send signals to breathe Type 3: Sleep-Related Hypoventilation · Decreased breathing leading to elevated carbon dioxide levels · Can be primary, medication-induced, or due to medical conditions --- Obstructive Sleep Apnea Hypopnea (OSA) Definition – What Is OSA? Obstructive Sleep Apnea Hypopnea is a breathing-related sleep disorder characterized by recurrent episodes of upper airway collapse during sleep, leading to reduced or absent airflow despite ongoing respiratory effort. Key feature: The patient is trying to breathe, but the airway is physically blocked. --- Epidemiology – Who Gets OSA? Prevalence: Very common · Approximately 10-20% of adults (mild to severe) · Up to 50% of older adults Gender: Males more affected than females (2-3 times higher), but risk increases in females after menopause Obesity: Strongest risk factor (70% of patients with OSA are obese) Age: Increases with age --- Risk Factors for OSA Strong risk factors: · Obesity (especially increased neck circumference) · Male gender · Older age · Family history of OSA Moderate risk factors: · Smoking · Nasal congestion · Supine sleeping position (on back) Other risk factors: · Craniofacial abnormalities (retrognathia, micrognathia, large tongue) · Hypothyroidism · Acromegaly · Down syndrome --- Pathophysiology – What Is Happening in OSA? During sleep (especially REM sleep): · Pharyngeal muscles relax excessively · The upper airway narrows or collapses completely · Airflow stops despite continued diaphragmatic effort · Oxygen levels drop (hypoxemia) · Carbon dioxide rises (hypercapnia) · The brain detects the problem and triggers an arousal (microarousal) · The patient takes a deep breath (snort, gasp) and airway reopens · This cycle repeats dozens or hundreds of times per night · Sleep is severely fragmented Consequences: · Sympathetic nervous system activation (increased blood pressure) · Oxidative stress and inflammation · Metabolic dysfunction (insulin resistance) · Daytime sleepiness from fragmented sleep --- Clinical Features of OSA Nighttime Features: · Loud, disruptive snoring · Witnessed apneas (breathing stops) by bed partner · Snorting, gasping, or choking sounds · Restless sleep · Frequent awakenings · Nocturia (waking to urinate multiple times) Daytime Features: · Excessive daytime sleepiness (most common complaint) · Unrefreshing sleep · Morning headache · Dry mouth or sore throat upon waking · Irritability and mood changes · Poor concentration and memory impairment · Decreased libido --- DSM-5 Diagnostic Criteria for OSA Criterion A: Polysomnography (sleep study) evidence of at least 5 obstructive apneas or hypopneas per hour of sleep (Apnea-Hypopnea Index or AHI of 5 or more) PLUS one of the following: · (1) Nocturnal breathing disturbances (snoring, snorting, gasping, breathing pauses) reported by the patient or bed partner · (2) Daytime sleepiness, fatigue, or unrefreshing sleep despite adequate opportunity to sleep OR Criterion B: Polysomnography evidence of 15 or more obstructive apneas and/or hypopneas per hour of sleep (AHI of 15 or more) regardless of symptoms Criterion C: The disturbance causes clinically significant distress or impairment in cognitive, social, occupational, or other functioning Criterion D: The disorder is not better explained by another sleep disorder, substance use, or medical condition --- Severity Specifiers for OSA Mild: · Apnea-Hypopnea Index (AHI) of 5 to 15 events per hour Moderate: · AHI of 15 to 30 events per hour Severe: · AHI greater than 30 events per hour Note: Severity is determined by AHI, but clinical severity also considers daytime symptoms and comorbidities. --- Central Sleep Apnea Definition – What Is Central Sleep Apnea? Central Sleep Apnea is a breathing-related sleep disorder characterized by recurrent episodes of cessation of respiratory effort during sleep due to the brainstem not sending signals to the breathing muscles. Key distinction from OSA: In central sleep apnea, there is no respiratory effort (the chest does not move). In OSA, there is effort but no airflow. --- Types of Central Sleep Apnea Primary Central Sleep Apnea: · No identifiable underlying cause Cheyne-Stokes Breathing: · Crescendo-decrescendo pattern of breathing followed by central apneas · Typically associated with heart failure, stroke, or renal failure Medication-Induced Central Sleep Apnea: · Most commonly caused by chronic opioid use (methadone, morphine, oxycodone) Central Sleep Apnea Comorbid with Opioid Use: · Specific specifier for opioid-related cases High-Altitude Periodic Breathing: · Occurs at high altitudes (above 4,000 meters) --- DSM-5 Diagnostic Criteria for Central Sleep Apnea Criterion A: Polysomnography shows at least 5 central apneas per hour of sleep Criterion B: The pattern of breathing shows at least one of the following: · (1) Cheyne-Stokes breathing pattern · (2) Periodic breathing at high altitude · (3) Central apneas induced by medication (opioids) Criterion C: The disturbance causes clinically significant distress or impairment Criterion D: Not better explained by another sleep disorder or medical condition --- Sleep-Related Hypoventilation Definition – What Is Sleep-Related Hypoventilation? Sleep-Related Hypoventilation is a breathing-related sleep disorder characterized by decreased ventilation during sleep leading to elevated carbon dioxide levels (hypercapnia) that cannot be explained by apneas or hypopneas alone. Key feature: The problem is not airway closure (OSA) or lack of effort (central apnea), but shallow breathing and inadequate gas exchange. --- DSM-5 Diagnostic Criteria for Sleep-Related Hypoventilation Criterion A: Polysomnography shows evidence of hypoventilation during sleep as demonstrated by: · Elevated carbon dioxide levels during sleep (PaCO2 greater than 55 mmHg for at least 10 minutes) · OR an increase in PaCO2 of at least 10 mmHg from awake to sleep (to a value exceeding 50 mmHg) Criterion B: The hypoventilation is not better explained by another sleep disorder (OSA, central apnea), substance use, or other medical condition Criterion C: The disturbance causes clinically significant distress or impairment Specify if: · With other medical comorbidity (e.g., COPD, neuromuscular disease) · With medication use · With other sleep disorder --- Treatment Overview for Breathing-Related Sleep Disorders Obstructive Sleep Apnea: · First-line: CPAP (Continuous Positive Airway Pressure) · Alternatives: Oral appliances (mandibular advancement devices), positional therapy, weight loss, surgery (UPPP, tonsillectomy) · Severe obesity: Bariatric surgery Central Sleep Apnea: · Adaptive Servo-Ventilation (ASV) for Cheyne-Stokes · CPAP or BPAP · Treatment of underlying cause (heart failure, opioid reduction) Sleep-Related Hypoventilation: · BPAP (Bi-level Positive Airway Pressure) or non-invasive ventilation · Treatment of underlying medical condition (COPD, neuromuscular disease) --- Prognosis for Breathing-Related Sleep Disorders Good with treatment: · CPAP dramatically improves sleepiness, quality of life, and cardiovascular outcomes · Blood pressure decreases · Accident rates decrease Poor if untreated: · Hypertension · Cardiovascular disease (heart failure, stroke, atrial fibrillation) · Metabolic syndrome and diabetes · Increased mortality · Chronic daytime sleepiness and disability Key quote: Obstructive sleep apnea is highly treatable. CPAP is one of the most effective treatments in all of medicine when used consistently. --- Final Summary of Key Points for Breathing-Related Sleep Disorders 1. Three types: OSA (airway collapse), central apnea (no effort), hypoventilation (shallow breathing) 2. OSA is the most common – risk factors include obesity, male gender, older age 3. Diagnosis requires polysomnography (sleep study) 4. Key clinical features: snoring, witnessed apneas, daytime sleepiness 5. First-line treatment for OSA is CPAP 6. Untreated OSA leads to cardiovascular disease and increased mortality 7. All three types cause sleep fragmentation and daytime impairment --- Circadian Rhythm Sleep-Wake Disorders Definition – What Are Circadian Rhythm Sleep-Wake Disorders? Circadian Rhythm Sleep-Wake Disorders are a persistent or recurrent pattern of sleep disruption primarily due to alteration of the circadian system or misalignment between the endogenous circadian rhythm and the required sleep-wake schedule driven by social, professional, or environmental demands. Key feature: The patient is unable to sleep when sleep is desired or required, but can sleep normally if allowed to follow their internal clock. --- Types of Circadian Rhythm Disorders (Six Types) Type 1: Delayed Sleep Phase Type Type 2: Advanced Sleep Phase Type Type 3: Irregular Sleep-Wake Type Type 4: Non-24-Hour Sleep-Wake Type Type 5: Shift Work Type Type 6: Unspecified Type --- DSM-5 Diagnostic Criteria (Applies to All Types) Criterion A: A persistent or recurrent pattern of sleep disruption that is primarily due to: · An alteration of the circadian system OR · Misalignment between the endogenous circadian rhythm and the individual's required sleep-wake schedule (social, professional, environmental) Criterion B: The sleep disruption leads to: · Excessive sleepiness, OR · Insomnia, OR · Both Criterion C: The sleep disturbance causes clinically significant distress or impairment in social, occupational, or other functioning Criteria D and E: Not better explained by another sleep disorder, substance use, or medical/mental condition --- Type 1: Delayed Sleep Phase Type Definition: A persistent pattern of delayed sleep onset and awakening times, with inability to fall asleep or awaken at conventionally acceptable earlier times. Key features: · Sleep onset typically 2-6 hours later than desired · Natural wake time is late morning or early afternoon · When allowed to follow their natural schedule, sleep quality and duration are normal · Extremely common in adolescents and young adults Clinical presentation: · Cannot fall asleep before 2 AM or 3 AM · Cannot wake up for school or work before 10 AM or 11 AM · Severe morning sleepiness and difficulty awakening · Afternoon and evening alertness are normal (or even increased) Specify if: Familial (genetic component often present) --- Type 2: Advanced Sleep Phase Type Definition: A persistent pattern of advanced sleep onset and awakening times, with inability to remain awake or asleep until desired later times. Key features: · Sleep onset typically 2-6 hours earlier than desired (e.g., 7 PM or 8 PM) · Natural wake time is very early morning (e.g., 3 AM or 4 AM) · When allowed to follow their natural schedule, sleep quality and duration are normal · More common in older adults Clinical presentation: · Cannot stay awake until normal bedtime (e.g., falls asleep during evening activities) · Wakes up extremely early (3-4 AM) and cannot go back to sleep · Morning alertness is normal but early afternoon sleepiness may occur Specify if: Familial --- Type 3: Irregular Sleep-Wake Type Definition: A temporally disorganized sleep-wake pattern with variable timing of sleep and wake periods throughout the 24-hour period. Key features: · No clearly defined main sleep period · Multiple short sleep episodes (naps) across the 24-hour day · Total sleep time is typically normal for age · Circadian rhythm appears absent or severely disrupted Clinical presentation: · Patient sleeps at different times each day · Daytime sleepiness is severe · Nighttime insomnia is present (when attempting to sleep at conventional hours) · Common in: institutionalized elderly, dementia patients, children with neurodevelopmental disorders --- Type 4: Non-24-Hour Sleep-Wake Type Definition: A persistent pattern of sleep-wake cycles that are not synchronized to the 24-hour environment, with a consistent daily drift to later times. Key features: · Endogenous circadian period is longer than 24 hours (typically 24.5 to 25 hours) · Sleep onset and wake times progressively drift later each day (by approximately 30-90 minutes) · The patient eventually cycles through alignment and misalignment with the external world · Extremely common in blind individuals (lack of light perception to entrain the circadian clock) Clinical presentation: · Periods of normal sleep followed by periods of severe insomnia and daytime sleepiness · Symptoms cycle over weeks to months · When the internal clock aligns with external day, sleep is normal · When misaligned, patient cannot sleep at night and is sleepy during the day Prevalence: Approximately 50-80% of totally blind individuals --- Type 5: Shift Work Type Definition: Insomnia during the major sleep period and/or excessive sleepiness during the major awake period associated with shift work schedule. Key features: · Symptoms directly related to work schedule that overlaps with the normal sleep period · Includes night shifts, early morning shifts, rotating shifts · Not due to another circadian rhythm disorder or sleep disorder Clinical presentation: · Difficulty falling asleep or staying asleep during daytime sleep (for night shift workers) · Excessive sleepiness during night work · Difficulty concentrating at work · Increased risk of accidents · Irritability and mood disturbance Prevalence: Very common – up to 10-30% of shift workers meet criteria Specifiers: · Episodic: 1 to 3 months · Persistent: 3 months or longer · Recurrent: Two or more episodes within one year --- Treatment Overview for Circadian Rhythm Disorders Delayed Sleep Phase: · Chronotherapy: Progressive delay of bedtime by 2-3 hours each day until desired schedule achieved · Morning bright light therapy (30-60 minutes upon awakening) · Low-dose melatonin 3-5 hours before desired bedtime · Strict adherence to early wake time, even on weekends Advanced Sleep Phase: · Evening bright light therapy (in the hours before desired bedtime) · Avoid morning light exposure · Melatonin not typically helpful Irregular Sleep-Wake: · Structured daytime activities · Scheduled physical activity · Morning bright light therapy · Avoid long daytime naps Non-24-Hour (Blind individuals): · Tasimelteon (FDA-approved, melatonin agonist at MT1/MT2 receptors) – taken at same time each evening · For sighted individuals: morning light therapy and evening melatonin Shift Work Type: · Strategic napping before and during shifts · Bright light exposure during night shift · Complete darkness during daytime sleep (blackout curtains, eye mask) · Modafinil or armodafinil (wake-promoting agents) for safety-critical jobs · Minimize rotating shifts; prefer forward rotation (day → evening → night) --- Prognosis Good with: · Correct identification of type · Appropriate light therapy and behavioral interventions · Workplace accommodations (for shift work) Poor if untreated: · Chronic sleep deprivation · Occupational and academic failure · Mood disorders (especially depression) · Substance use (caffeine, alcohol, sleeping pills) Key quote: Circadian rhythm disorders are highly treatable with time-appropriate light exposure and behavioral changes, but they are often misdiagnosed as insomnia or hypersomnia. --- Final Summary of Key Points for Circadian Rhythm Disorders 1. Six types: delayed phase, advanced phase, irregular, non-24-hour, shift work, unspecified 2. Core problem: mismatch between internal clock and external demands 3. Sleep quality is normal when patient follows their natural schedule 4. Diagnosis requires careful sleep diary (2+ weeks) and sometimes actigraphy 5. Treatment uses light therapy at specific times (morning for delayed phase, evening for advanced phase) 6. Melatonin and tasimelteon are helpful for some types 7. Shift work type is very common and often undertreated --- Non-Rapid Eye Movement (NREM) Sleep Arousal Disorders Definition – What Are NREM Sleep Arousal Disorders? NREM Sleep Arousal Disorders are characterized by recurrent episodes of incomplete awakening from sleep, typically occurring during NREM sleep (usually in the first third of the night). The patient has reduced awareness and responsiveness and partial or complete amnesia for the episode. Two types: Sleepwalking Type and Sleep Terror Type. --- DSM-5 Diagnostic Criteria (Applies to Both Types) Criterion A: Recurrent episodes of incomplete awakening from sleep, usually occurring during the first third of the major sleep episode Criterion B: During each episode, at least one of the following is present: · Sleepwalking: getting out of bed and walking about · Sleep terrors: abrupt terror arousals with screaming, intense fear, and autonomic arousal Criterion C: During the episode, the individual has: · Reduced or absent responsiveness to others' efforts to intervene · Limited or no associated cognition or dream imagery · Partial or complete amnesia for the episode Criterion D: The episodes cause clinically significant distress or impairment in social, occupational, or other functioning Criterion E: Not attributable to substance use or other medical/mental conditions --- Type 1: Sleepwalking Type (Somnambulism) Definition: Repeated episodes of complex motor behaviors performed during NREM sleep, including getting out of bed and walking about. Clinical features: · Patient sits up, opens eyes, and gets out of bed · Walking may be purposeful or aimless · May perform complex behaviors (opening doors, eating, dressing, even driving) · Eyes are open but patient appears dazed or glassy-eyed · Speech is slow, monotone, or absent · Does not respond to questions or responds inappropriately · Can be difficult to wake and may become confused or aggressive if woken · Episode typically lasts minutes to 30 minutes · Complete amnesia for the episode in the morning Triggers: Sleep deprivation, stress, fever, alcohol, certain medications (zolpidem). Prevalence: Up to 15% of children, 2-4% of adults. --- Type 2: Sleep Terror Type (Night Terrors, Pavor Nocturnus) Definition: Recurrent episodes of abrupt terror arousals from NREM sleep, characterized by intense fear and autonomic arousal. Clinical features: · Sudden sitting up in bed with a piercing scream or cry · Intense fear, panic, and extreme autonomic arousal: · Tachycardia (rapid heart rate) · Tachypnea (rapid breathing) · Sweating, flushing, dilated pupils · Increased muscle tone (rigid, may fight or thrash) · The patient is unresponsive to comfort or reassurance · Does not recall a detailed dream (unlike nightmares) · Difficulty awakening the patient; if awakened, disoriented · No memory of the event the next morning · Episodes typically last 1 to 10 minutes Triggers: Same as sleepwalking – sleep deprivation, stress, fever, alcohol. Prevalence: 1-6% of children, less than 1% of adults. Key distinction from nightmares: · Night terrors occur in NREM sleep (first third of night) · Nightmares occur in REM sleep (last third of night) · Night terrors: no dream recall, unresponsive, amnesia · Nightmares: vivid recall, fully awake after, distress is emotional --- Specifiers for NREM Sleep Arousal Disorders Specify if: · With non-sleep disorder mental comorbidity · With other medical comorbidity · With other sleep disorder Course Specifiers: · Episodic: 1 to 3 months · Persistent: More than 3 months · Recurrent: Two or more episodes within one year Severity: · Mild: Less than 1 episode per week · Moderate: 1 or more episodes per week but not nightly · Severe: Nightly episodes --- Differential Diagnosis Nightmare Disorder: · Key distinction: Nightmares occur in REM sleep, vivid recall, full awakening, in last third of night REM Sleep Behavior Disorder: · Key distinction: Occurs in REM sleep (not NREM), involves dream enactment, patient can be woken easily and is not confused or amnestic Seizures (Nocturnal Frontal Lobe Epilepsy): · Key distinction: Very brief episodes (seconds), stereotyped movements, multiple per night, EEG abnormalities Dissociative Disorders: · Key distinction: Episodes occur during wakefulness, not exclusively from sleep, more complex behaviors Factitious Disorder or Malingering: · Key distinction: Inconsistent with typical sleep physiology, patient aware of behaviors, secondary gain present --- Comorbidity NREM arousal disorders frequently co-occur with: · Obstructive sleep apnea (can trigger episodes) · Restless legs syndrome · Migraine headaches · Enuresis (bedwetting) in children · Psychiatric disorders in adults (PTSD, anxiety, depression) · Medication use (zolpidem, other sedative-hypnotics) --- Functional Consequences Untreated NREM arousal disorders can lead to: · Injury to patient (falling down stairs, walking into objects, leaving the house) · Injury to bed partner (hitting, kicking during episodes) · Severe embarrassment and social isolation · Disrupted sleep for family members · Legal consequences (rare cases of sleep-related violence or driving) · Marital conflict and relationship strain --- Treatment (Part 1 of 2 – Non-Pharmacological) First-Line Non-Pharmacological Treatment: 1. Reassurance and education · Explain that the patient is not aware and not responsible · Reduce family anxiety 2. Sleep hygiene optimization · Ensure adequate total sleep time · Regular sleep-wake schedule · Avoid sleep deprivation (most important trigger) 3. Trigger identification and avoidance · Reduce stress before bedtime · Avoid alcohol before sleep · Review and adjust medications (especially zolpidem) · Treat fever or underlying illness 4. Safety measures (crucial) · Lock doors and windows · Remove sharp objects and tripping hazards · Stair gates · Alarm systems on doors · Move patient to ground floor if needed 5. Scheduled awakenings · Gently awaken the patient 15-30 minutes before typical episode time · Keep awake for a few minutes · Repeat for 2-4 weeks --- Treatment (Part 2 of 2 – Pharmacological) Pharmacological Treatment (for severe, dangerous, or refractory cases): Benzodiazepines: · Clonazepam (most studied, highly effective) · Low dose at bedtime · Caution: Tolerance, dependence, daytime sedation, falls (especially in elderly) Antidepressants: · Paroxetine (SSRI) · Amitriptyline (tricyclic) · Limited evidence but may reduce episodes Medications to avoid: · Zolpidem and other non-benzodiazepine hypnotics (can induce sleepwalking and sleep eating) Rule: Medication is second-line. Most patients respond to sleep hygiene and safety measures alone. --- Prognosis Children: · Excellent – most children outgrow sleepwalking and sleep terrors by adolescence · No treatment needed beyond safety and reassurance Adults: · More variable – may persist for years · Good if triggers (sleep deprivation, stress) are controlled · May require medication if dangerous behaviors persist Key quote: For children, NREM arousal disorders are common and usually benign. For adults with dangerous behaviors, active treatment is essential. --- Final Summary of Key Points for NREM Sleep Arousal Disorders 1. Two types: sleepwalking and sleep terrors (night terrors) 2. Occur during NREM sleep (first third of the night) 3. Key features: reduced responsiveness, no dream recall, amnesia 4. Common in children (up to 15%) less common in adults 5. Primary triggers: sleep deprivation, stress, fever, alcohol 6. First-line treatment: safety measures, adequate sleep, trigger avoidance 7. Medications (clonazepam) only for severe or dangerous cases 8. Children usually outgrow it; adults may need long-term management --- Nightmare Disorder Definition – What Is Nightmare Disorder? Nightmare Disorder is characterized by repeated occurrences of extended, dysphoric, and well-remembered dreams that generally involve threats to survival, security, or physical integrity. On awakening, the individual becomes rapidly oriented and alert. Key distinction from sleep terrors: Nightmares occur in REM sleep, the patient wakes completely, and vividly recalls the dream content. --- DSM-5 Diagnostic Criteria Criterion A: Repeated occurrences of extended, dysphoric, and well-remembered dreams that usually involve efforts to avoid threats to survival, security, or physical integrity Criterion B: On awakening from the nightmare, the individual becomes rapidly oriented and alert (not confused like in sleep terrors) Criterion C: The nightmares cause clinically significant distress or impairment in social, occupational, or other functioning Criterion D: The symptoms are not attributable to substance effects (e.g., medication, alcohol, drug withdrawal) or other medical conditions --- Specifiers Specify if: · During sleep onset (nightmares that occur while falling asleep – rare) Specify if associated with another disorder: · Associated with another mental disorder (especially PTSD, anxiety disorders, borderline personality disorder) · Associated with medical condition · Associated with another sleep disorder Specify severity: · Mild: Less than one episode per week on average · Moderate: One or more episodes per week but less than nightly · Severe: Nightly episodes --- Epidemiology – Who Gets It? Prevalence: · Children: Up to 50% experience occasional nightmares · Adults: Approximately 2-8% meet full criteria for nightmare disorder Gender: More common in females (adults), but equal in children Onset: Can begin at any age, but most common in childhood (ages 3-12) --- Risk Factors Psychological: · Post-Traumatic Stress Disorder (PTSD) – nightmares are a core diagnostic feature · Anxiety disorders · Borderline personality disorder · Schizophrenia · Acute stress disorder Environmental: · Stressful life events · Trauma exposure · History of childhood abuse Genetic: · Family history of nightmares or dream recall Medications: · Some antidepressants (SSRIs, SNRIs can cause vivid dreams) · Beta-blockers · Dopamine agonists (for Parkinson's) · Cholinergic medications · Withdrawal from REM-suppressing medications (alcohol, benzodiazepines) --- Pathophysiology – What Is Happening in the Brain? Nightmares occur during REM sleep (rapid eye movement sleep). In normal REM sleep: · The brain is highly active (similar to wakefulness) · Vivid dreaming occurs · Motor paralysis (atonia) prevents dream enactment In nightmare disorder: · REM sleep is preserved but with increased negative affect · Amygdala hyperactivation (fear processing) · Impaired fear extinction mechanisms · Possible noradrenergic overactivity during REM sleep · For PTSD-related nightmares: increased REM density and sleep fragmentation --- Clinical Features Nighttime Features: · Awakening from REM sleep (typically in the last third of the night) · Vivid, detailed, and frightening dream recall · Dreams often involve threat to survival or physical integrity · Upon awakening: rapid orientation, full alertness · Difficulty returning to sleep (due to fear of having another nightmare) Daytime Features: · Fatigue from disrupted sleep · Fear of going to sleep (sleep anxiety, avoidant bedtime behavior) · Daytime distress about nightmare content (intrusive imagery) · Impaired concentration and mood disturbance · Avoidance of triggers related to nightmare content --- Differential Diagnosis (What Else Could It Be?) Sleep Terrors (Night Terrors): · Key distinction: NREM sleep, first third of night, no dream recall, unresponsive, amnesia, autonomic arousal REM Sleep Behavior Disorder: · Key distinction: Dream enactment (motor behaviors), not just reported dreams, occurs in older men, associated with neurodegeneration PTSD-Related Nightmares: · Nightmares are a core criterion for PTSD diagnosis · Key distinction: Recurrent dreams directly related to traumatic event · If PTSD is present and nightmares are part of trauma re-experiencing, diagnose PTSD, not nightmare disorder Medication-Induced Nightmares: · Key distinction: Symptoms begin within 1 month of starting or withdrawing medication · Diagnose substance/medication-induced sleep disorder No Disorder (Normal Nightmares): · Key distinction: No clinically significant distress or impairment --- Comorbidity (Frequently Associated Conditions) Nightmare disorder very frequently co-occurs with: · Post-Traumatic Stress Disorder (PTSD) – extremely common (50-90% of PTSD patients have nightmares) · Anxiety disorders (generalized anxiety, panic disorder) · Major Depressive Disorder · Borderline Personality Disorder · Schizophrenia · Sleep apnea, restless legs syndrome (can increase dream recall and nightmares) · Substance use disorders (especially alcohol and benzodiazepine withdrawal) Principle: In PTSD, treat the trauma first – nightmares often improve with trauma-focused therapy. --- Functional Consequences Untreated nightmare disorder leads to: · Severe sleep avoidance (fear of going to bed, sleep deprivation) · Daytime fatigue and cognitive impairment · Mood disturbance (irritability, depression, anxiety) · Impaired work and academic performance · Social withdrawal · Increased suicide risk (in severe cases, especially with PTSD) --- Treatment (Part 1 of 2 – Non-Pharmacological) First-Line Non-Pharmacological Treatment: 1. Image Rehearsal Therapy (IRT) – strongest evidence · Patient recalls a nightmare and changes it to a neutral or positive story · Rehearses the new dream daily for 10-20 minutes · Reduces frequency and intensity of nightmares 2. Exposure, Relaxation, and Rescripting Therapy (ERRT) · Combines education, relaxation training, exposure to nightmare content, and rescripting 3. Cognitive Behavioral Therapy for Nightmares (CBT-N) · Identifies and changes maladaptive beliefs about nightmares · Sleep hygiene and relaxation training 4. Lucid Dreaming Therapy · Patient learns to recognize they are dreaming while still asleep · Can then change the dream content 5. Treatment of underlying condition (especially PTSD, anxiety) --- Treatment (Part 2 of 2 – Pharmacological) Pharmacological Treatment (Second-line or adjunctive): First-line medications (for PTSD-related nightmares): · Prazosin (alpha-1 adrenergic antagonist) · Reduces noradrenergic activity during REM sleep · Highly effective for trauma-related nightmares · Start at 1 mg at bedtime, titrate to 5-15 mg Other medications (limited evidence): · Clonidine (similar mechanism to prazosin, but less evidence) · Trazodone (sedating antidepressant) · Topiramate (anticonvulsant) · Atypical antipsychotics (for severe, refractory cases – caution for side effects) Medications to avoid in nightmare disorder: · SSRIs and SNRIs (can cause or worsen nightmares in some patients, though they treat underlying PTSD) Rule: Image Rehearsal Therapy and Prazosin are the two best-supported treatments. --- Prognosis Good with treatment: · Image Rehearsal Therapy: 70-80% reduction in nightmare frequency · Prazosin: similar efficacy for PTSD-related nightmares · Many patients achieve complete remission Poor if untreated: · Chronic nightmares can persist for years or decades · High comorbidity with depression, anxiety, and suicide risk Key quote: Nightmare disorder is highly treatable. Image Rehearsal Therapy and Prazosin are effective and underutilized. --- Final Summary of Key Points 1. Nightmare Disorder involves repeated, well-remembered, frightening dreams 2. Nightmares occur during REM sleep (last third of the night) 3. Patient wakes fully alert and can describe the dream in detail 4. Key differentials: sleep terrors (NREM, no recall), REM sleep behavior disorder (motor enactment), PTSD (trauma content) 5. Very common in PTSD (up to 90%) 6. First-line treatment: Image Rehearsal Therapy 7. First-line medication: Prazosin (especially for PTSD-related nightmares) 8. Prognosis is excellent with treatment --- REM Sleep Behavior Disorder Definition – What Is REM Sleep Behavior Disorder? REM Sleep Behavior Disorder is characterized by repeated episodes of arousal during REM sleep associated with vocalization and complex motor behaviors that enact dream content. The patient loses the normal muscle paralysis (atonia) that occurs during REM sleep, allowing them to physically act out their dreams. Key feature: Dream enactment. Unlike sleepwalking, the patient can vividly recall the dream and is not confused upon awakening. --- DSM-5 Diagnostic Criteria Criterion A: Repeated episodes of arousal during REM sleep, as documented by polysomnography, associated with vocalization and/or complex motor behaviors Criterion B: The behaviors arise during REM sleep and are documented to occur during REM sleep (by polysomnography or clinical history of dream enactment) Criterion C: Upon awakening from the episode, the individual is fully alert and not confused or disoriented Criterion D: The episodes cause clinically significant distress or impairment, or they lead to self-injury or injury to the bed partner Criterion E: Not attributable to substance effects or other medical/mental conditions --- Epidemiology – Who Gets It? Prevalence: Approximately 0.5-1% of general population, but much higher in older adults Age of onset: Typically after age 50 (mean onset around 60 years) Gender: Much more common in males (approximately 80-90% of cases) Key fact: REM sleep behavior disorder is a strong prodromal marker for neurodegenerative diseases, especially synucleinopathies. --- Risk Factors Strong risk factors: · Older age · Male gender · Family history of REM sleep behavior disorder or Parkinson's disease Medical risk factors: · Synucleinopathies (see below) · Narcolepsy Type 1 (overlap with cataplexy) · Brainstem lesions (stroke, tumor, multiple sclerosis) · Head trauma Medication-induced (can mimic or unmask RBD): · SSRIs and SNRIs (especially high doses) · MAOIs (monoamine oxidase inhibitors) · Cholinesterase inhibitors · Mirtazapine · Withdrawal from benzodiazepines or alcohol --- Pathophysiology – What Is Happening in the Brain? In normal REM sleep: · The brainstem (specifically the sublaterodorsal nucleus and the ventromedial medulla) sends signals that inhibit motor neurons · This produces REM atonia: the body is paralyzed except for the eyes and diaphragm · This prevents dream enactment In REM sleep behavior disorder: · Loss of REM atonia due to dysfunction of brainstem pathways · Motor neurons remain active during REM sleep · The patient physically acts out dream content · Typically associated with neurodegeneration in the brainstem (especially the locus coeruleus, pedunculopontine nucleus) Strong association with alpha-synuclein pathology: · REM sleep behavior disorder precedes Parkinson's disease by 5-15 years in up to 80% of cases · Also associated with dementia with Lewy bodies and multiple system atrophy Rarely, RBD can be caused by a discrete brainstem lesion (stroke, tumor, inflammatory). --- Clinical Features Nighttime Features: · Dream enactment behaviors during REM sleep (usually second half of the night, when REM sleep is more abundant) · Behaviors often match dream content (fighting off an attacker, running, swimming, catching something) · Examples: punching, kicking, leaping from bed, yelling, swearing, laughing, grabbing · Vocalizations (talking, shouting, screaming) · Bed partner injuries are common (bruises, fractures, scratches) · Self-injury (falling from bed, hitting walls or furniture) · Upon awakening: fully alert, not confused, can vividly recall the dream (often violent or action-packed) Morning Features (may be reported by bed partner): · Bed in disarray · Patient found on floor · Bed partner injured or unwilling to share the bed --- Differential Diagnosis (What Else Could It Be?) Nightmare Disorder: · Key distinction: No dream enactment (patient remains still) · No injury to self or partner · No loss of REM atonia on polysomnography Sleepwalking (NREM Arousal Disorder): · Key distinction: Occurs in NREM sleep (first third of night) · Confusion upon awakening, amnesia · Less violent behaviors typically Nocturnal Seizures (Frontal Lobe Epilepsy): · Key distinction: Very brief episodes (seconds), stereotyped movements, multiple per night · EEG abnormalities · No dream recall Sleep-Related Eating Disorder: · Key distinction: Compulsive eating during NREM sleep · Not associated with dreaming · No violent behaviors Severe Periodic Limb Movement Disorder: · Key distinction: Simple repetitive movements (kicking, leg twitching) · Not complex dream enactment --- Comorbidity (Frequently Associated Conditions) REM sleep behavior disorder is strongly associated with: Neurodegenerative synucleinopathies (up to 80-90% convert within 10-15 years): · Parkinson's disease (most common) · Dementia with Lewy bodies · Multiple system atrophy Other associations: · Narcolepsy Type 1 (up to 25% of narcolepsy patients have RBD-like symptoms) · Post-traumatic stress disorder (possibly) · Stroke or brainstem lesions (rare) Principle: An older male presenting with violent dream enactment should be evaluated for prodromal Parkinson's disease and followed longitudinally. --- Functional Consequences Untreated REM sleep behavior disorder leads to: · Significant injury to bed partner (black eyes, fractures, subdural hematomas – serious) · Self-injury (falls, lacerations, fractures) · Bed partner refuses to share bed (marital strain, separate bedrooms) · Poor sleep quality for both partners · Embarrassment and social avoidance (fear of sleeping in the same room as others) · Underlying neurodegenerative disease progression (RBD is a marker, not a cause) --- Treatment (Part 1 of 2 – Non-Pharmacological) First-Line Non-Pharmacological Interventions (Safety is priority): 1. Environmental safety (essential for all patients): · Remove sharp objects, furniture, and tripping hazards from near the bed · Pad the floor next to the bed with cushions or mats · Place mattress on the floor (prevents fall injuries) · Use padded bed rails · Protect windows (remove nearby beds) · Lock bedroom door (prevents leaving the house) · Move breakable items out of the bedroom 2. Bed partner safety: · Separate beds or bedrooms if severe · Place a pillow barrier between partners · Bed partner should not try to wake the patient during episodes 3. Sleep hygiene: · Regular sleep schedule · Avoid sleep deprivation (can worsen episodes) · Avoid alcohol before bedtime (can trigger episodes) 4. Identify and stop causative medications: · Review SSRIs, SNRIs, MAOIs, mirtazapine, cholinesterase inhibitors · Change or discontinue if possible --- Treatment (Part 2 of 2 – Pharmacological) Pharmacological Treatment (Highly effective, often needed): First-line medication: · Clonazepam (benzodiazepine) · 0.5 to 2.0 mg at bedtime · Reduces or eliminates dream enactment in 80-90% of patients · Caution: falls, cognitive side effects (especially in elderly), tolerance, dependence · Use lowest effective dose Second-line medications (when clonazepam is not tolerated or contraindicated): · Melatonin (high-dose: 3 to 15 mg at bedtime) · Fewer side effects, especially in elderly · May take 4-8 weeks to work · Often used as first-line in elderly or cognitively impaired patients · Pramipexole (dopamine agonist) · Limited evidence · Rivastigmine (cholinesterase inhibitor) · For RBD with dementia Medications to avoid: SSRIs and SNRIs (can worsen or trigger RBD) Rule: Clonazepam is highly effective but use cautiously in elderly due to fall risk. Melatonin is safer first-line in older patients. --- Prognosis Good with treatment: · Medications (clonazepam or melatonin) are highly effective · Injury risk dramatically decreased · No cure, but symptoms can be controlled Prognosis for underlying disease: · REM sleep behavior disorder is not itself fatal, but it is a strong predictor of synucleinopathy · Within 5 years: approximately 30-40% develop Parkinson's or dementia with Lewy bodies · Within 10-15 years: up to 80-90% develop a synucleinopathy · All patients with RBD should be monitored neurologically for signs of parkinsonism or cognitive decline Key quote: Treating RBD prevents injury, but the condition is a harbinger of Parkinson's disease. These patients need neurological follow-up. --- Final Summary of Key Points for REM Sleep Behavior Disorder 1. Loss of REM atonia leads to dream enactment (punching, kicking, yelling) 2. Occurs in REM sleep (second half of the night) 3. Upon awakening: fully alert, not confused, dreams vividly recalled 4. Strongly associated with synucleinopathies (Parkinson's, dementia with Lewy bodies) 5. Up to 80-90% of older males with RBD develop Parkinson's within 10-15 years 6. First-line: environmental safety and clonazepam or high-dose melatonin 7. Bed partner injury is common – treat aggressively 8. All patients need neurological monitoring for underlying neurodegenerative disease --- Restless Legs Syndrome (RLS) Definition – What Is Restless Legs Syndrome? Restless Legs Syndrome (RLS) is characterized by an urge to move the legs, usually accompanied by uncomfortable and unpleasant sensations. The urge to move begins or worsens during rest or inactivity, is partially or totally relieved by movement, and occurs only or is worse in the evening or at night. Key feature: The urge to move the legs with three characteristic features (rest-induced, movement-relieved, evening/night-worsening). --- DSM-5 Diagnostic Criteria Criterion A: An urge to move the legs, usually accompanied by or felt to be caused by uncomfortable and unpleasant sensations in the legs Criterion B: The urge to move the legs has all three of the following characteristics: · (1) Begins or worsens during periods of rest or inactivity (lying down, sitting) · (2) Is partially or totally relieved by movement (walking, stretching, kicking) · (3) Occurs only or is worse in the evening or at night Criterion C: The symptoms occur at least 3 times per week Criterion D: The symptoms have persisted for at least 3 months Criterion E: The symptoms cause significant distress or impairment in social, occupational, educational, academic, behavioral, or other functioning Criterion F: The symptoms are not attributable to another medical or mental condition or substance effects (e.g., venous stasis, leg edema, arthritis, leg cramps, positional discomfort, habitual foot tapping) --- Epidemiology – Who Gets It? Prevalence: · Approximately 2-10% of the general population · 1-2% have moderate to severe symptoms requiring treatment · More common in Caucasians (lower prevalence in Asian and African populations) Gender: More common in females (approximately 2:1) Age of onset: Bimodal – early onset (before age 45) and late onset (after age 45) --- Types of Restless Legs Syndrome Early-Onset RLS (before age 45): · More likely to have genetic cause · Often familial (autosomal dominant inheritance) · Slower progression · Less severe iron deficiency association Late-Onset RLS (after age 45): · More likely secondary to medical conditions · Faster progression · Stronger association with iron deficiency and neuropathy · More severe symptoms typically Types by etiology: · Primary (idiopathic) RLS – genetic, no identifiable cause · Secondary RLS – due to iron deficiency, pregnancy, uremia (kidney failure), neuropathy, medications --- Risk Factors Genetic: · Family history (50-70% of cases) · Genes identified: BTBD9, MEIS1, PTPRD, MAP2K5, LBXCOR1 · Early-onset RLS is highly heritable Medical conditions: · Iron deficiency (even without anemia) – strongest known risk factor · End-stage renal disease (uremia – up to 50% of dialysis patients) · Peripheral neuropathy · Diabetes mellitus · Rheumatoid arthritis · Pregnancy (especially third trimester – symptoms usually resolve after delivery) · Parkinson's disease Medications (can induce or worsen RLS): · Antidepressants (SSRIs, SNRIs, mirtazapine, bupropion) · Antihistamines (diphenhydramine) · Dopamine antagonists (antipsychotics, antiemetics like metoclopramide) · Some calcium channel blockers Lifestyle: · Caffeine intake · Alcohol use · Sleep deprivation --- Pathophysiology – What Is Happening in the Brain? Leading theories: 1. Iron deficiency in the brain: · Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme for dopamine synthesis · Brain iron deficiency (especially in the substantia nigra and striatum) leads to dopamine dysfunction · Serum ferritin may be low normal, but cerebrospinal fluid iron is low · Explains why iron supplementation helps even with normal serum ferritin 2. Dopamine dysfunction: · RLS responds dramatically to dopamine agonists (levodopa, pramipexole, ropinirole) · Symptoms peak in the evening/night when dopamine is naturally lower · Support for a circadian variation in dopamine transmission 3. Genetic factors: · Multiple identified genes involved in neuronal development and iron regulation 4. Spinal cord hyperexcitability: · Possibly due to reduced inhibition in spinal cord sensory pathways --- Clinical Features Sensorimotor features: · Urge to move the legs (mandatory diagnostic feature) · Unpleasant leg sensations described as: · Crawling, creeping, pulling, aching, itching, electrical, burning, or "bugs inside the legs" · Not typically pain (though pain may occur) · Sensory symptoms occur deep inside the legs (not on the skin) Temporal pattern (the three diagnostic criteria): · Rest-induced: Begins or worsens when sitting or lying down (e.g., during meetings, car rides, watching TV, trying to fall asleep) · Movement-relieved: Relieved by walking, stretching, kicking, or moving the legs; relief usually begins within seconds and lasts as long as movement continues · Evening/night-worsening: Symptoms are minimal in the morning and early afternoon, peak in evening and night (circadian pattern) Motor features (involuntary): · Periodic Limb Movements of Sleep (PLMS) – present in 80-90% of RLS patients · Repetitive, stereotyped leg jerks (extension of big toe, flexion of ankle, knee, hip) · Occurs every 20-40 seconds during sleep (especially NREM sleep) · Can cause sleep fragmentation and daytime sleepiness · Bed partner may be kicked or disturbed Consequences: · Severe sleep-onset insomnia (cannot keep legs still to fall asleep) · Sleep maintenance insomnia (leg jerks or urge to move wakes patient) · Daytime fatigue and sleepiness · Mood disturbance (irritability, depression, anxiety) --- Differential Diagnosis (What Else Could It Be?) Venous stasis or leg edema: · Key distinction: Sensation improves with leg elevation (RLS improves with movement, not elevation) · Visible leg swelling Peripheral neuropathy: · Key distinction: Symptoms are constant (not just at rest), pain is prominent, not relieved by movement, no circadian pattern · May co-exist with RLS Neurogenic claudication (spinal stenosis): · Key distinction: Relief with sitting and bending forward, not walking; pain (not urge to move) Akathisia (from antipsychotic medications): · Key distinction: Generalized sense of inner restlessness (not just legs) · Symptoms are constant (not evening-worsened) · Not relieved by movement in the same way Leg cramps: · Key distinction: Brief, painful, visible muscle hardening, not an urge to move Positional discomfort: · Key distinction: No urge to move, simply uncomfortable position, resolves with repositioning (not walking) Nocturnal leg myoclonus (benign): · Key distinction: No urge to move (only leg jerks), no sensory symptoms --- Comorbidity (Frequently Associated Conditions) RLS frequently co-occurs with: · Iron deficiency (most common secondary cause) · End-stage renal disease (up to 50% of dialysis patients) · Peripheral neuropathy · Diabetes · Parkinson's disease (10-20% of patients) · Pregnancy (up to 20-30% in third trimester) · Obstructive sleep apnea (overlap common) · Depression and anxiety (bidirectional – RLS causes sleep loss that worsens mood, and psychiatric medications can worsen RLS) · Cardiovascular disease (hypertension, coronary artery disease) – possibly due to chronic sympathetic activation Principle: All RLS patients should have ferritin and transferrin saturation checked. --- Functional Consequences Untreated RLS leads to: · Severe chronic insomnia (sleep-onset and sleep-maintenance) · Daytime fatigue and sleepiness · Depression and suicidal ideation (chronic pain-like condition) · Reduced quality of life (comparable to type 2 diabetes or chronic kidney disease) · Marital strain (bed partner disturbed by leg movements) · Travel avoidance (cannot sit through long flights, car rides, meetings) · Occupational impairment (cannot sit through meetings or desk work in the evening) --- Treatment (Part 1 of 2 – Non-Pharmacological and General Measures) First-Line Non-Pharmacological Interventions: 1. Identify and treat underlying causes: · Iron deficiency: oral or intravenous iron if ferritin < 75-100 mcg/L · Pregnancy: usually resolves postpartum; treat conservatively · Uremia: kidney transplantation or dialysis optimization · Neuropathy: treat underlying cause 2. Discontinue exacerbating medications: · Antidepressants (SSRIs, SNRIs, mirtazapine – often a clinical dilemma) · Antihistamines (diphenhydramine) · Dopamine antagonists (antipsychotics, antiemetics) · Caffeine, alcohol (especially in evening) 3. Behavioral and lifestyle measures: · Regular moderate exercise (but avoid late evening exercise) · Avoid sleep deprivation (can worsen symptoms) · Leg stretching, massage, warm baths before bed · Good sleep hygiene 4. Counterstimulation during rest: · Walking, stretching, leg movements during periods of required sitting --- Treatment (Part 2 of 2 – Pharmacological) Pharmacological Treatment (for moderate to severe RLS): First-line (for nightly or frequent symptoms): · Alpha-2-delta ligands (gabapentin, gabapentin enacarbil, pregabalin) · Best choice for patients with pain, insomnia, or comorbid anxiety · Lower risk of augmentation (see below) · Gabapentin enacarbil is FDA-approved for RLS · Start low (gabapentin 300 mg) and titrate Second-line (historically first, but now later due to augmentation risk): · Dopamine agonists (pramipexole, ropinirole) · Highly effective and fast-acting · But high risk of augmentation (worsening of symptoms: earlier onset, spread to arms, increased severity) · Risk increases with higher doses and longer duration · Rotigotine (transdermal patch) also available · Use only for intermittent symptoms (not nightly) if possible Third-line and adjunctive: · Benzodiazepines (clonazepam) – improves sleep quality but does not reduce leg urges; risk of dependence · Opioids (tramadol, oxycodone) – for refractory, severe, or augmentation cases; use cautiously · Iron supplementation (oral or IV) – if ferritin < 75 mcg/L Important clinical warning: Augmentation is a specific complication of dopamine agonists in RLS: · Symptoms become more severe · Start earlier in the day (morning or afternoon) · Spread to arms or trunk · Occurs in 50-70% of patients after years of dopamine agonist use · Treatment: taper dopamine agonist and switch to alpha-2-delta ligand Rule: For daily RLS, start with gabapentin or pregabalin. Reserve dopamine agonists for intermittent use only. --- Prognosis Good with treatment: · Most patients achieve significant symptom relief · Quality of life improves dramatically · Sleep normalizes with effective medication Poor if untreated: · Chronic insomnia and daytime impairment persist · Depression risk increases · Augmentation if dopamine agonists are mismanaged Prognosis by type: · Early-onset RLS: lifelong condition but slowly progressive · Late-onset RLS: may progress more rapidly and is more likely secondary to iron deficiency or medical condition · Pregnancy-related RLS: excellent – resolves after delivery in 90% of cases Key quote: Restless Legs Syndrome is a common, highly treatable cause of insomnia. Always check ferritin. Avoid dopamine agonists for daily use due to augmentation risk. --- Final Summary of Key Points for Restless Legs Syndrome 1. Urge to move legs with three key features: rest-induced, movement-relieved, evening/night-worsened 2. Prevalence: 2-10% of the population 3. Strong associations: iron deficiency, pregnancy, uremia, family history 4. All patients need ferritin checked 5. First-line medication for daily symptoms: gabapentin or pregabalin 6. Dopamine agonists (pramipexole, ropinirole) are effective but cause augmentation in 50-70% after years of use 7. Augmentation: earlier onset, more severe, spread to arms – requires stopping dopamine agonist 8. Prognosis excellent with proper treatment --- Substance/Medication-Induced Sleep Disorder Definition – What Is Substance/Medication-Induced Sleep Disorder? Substance/Medication-Induced Sleep Disorder is a prominent sleep disturbance (insomnia or excessive sleepiness) that develops within 1 month of substance intoxication or withdrawal, or after taking a medication. The disturbance is not better explained by a non-substance-induced sleep disorder. Key feature: Clear temporal relationship between substance use/discontinuation and the onset of sleep symptoms. --- DSM-5 Diagnostic Criteria Criterion A: A prominent sleep disturbance (insomnia or excessive sleepiness) Criterion B: The sleep disturbance developed within 1 month of: · Substance intoxication, or · Substance withdrawal, or · After taking a medication (including starting, stopping, or changing dose) Criterion C: The disturbance is not better explained by a sleep disorder that is not substance-induced (e.g., a pre-existing insomnia disorder) Criterion D: The disturbance does not occur exclusively during the course of a delirium Criterion E: The disturbance causes clinically significant distress or impairment --- Specifiers Specify if: · With insomnia type · With hypersomnia type · With parasomnia type (e.g., sleepwalking, REM sleep behavior disorder) · With mixed type (insomnia and hypersomnia) Specify onset: · During intoxication · During withdrawal · During medication use Specify if substance is identified: · Alcohol · Caffeine · Cannabis · Cocaine · Opioids · Sedatives, hypnotics, or anxiolytics · Stimulants · Tobacco · Other (specify) --- Common Substance-Induced Sleep Disorders by Substance Alcohol: · During intoxication: insomnia (falling asleep but fragmented sleep, early morning awakening) · During withdrawal: severe insomnia, nightmares (can last days to weeks) Caffeine: · During intoxication: insomnia (difficulty falling asleep, decreased total sleep time) Cannabis: · During intoxication: less REM sleep, less dreaming · During withdrawal: severe insomnia, nightmares, vivid dreams (rebound) Cocaine: · During intoxication: insomnia, total sleep deprivation · During withdrawal: hypersomnia (excessive sleepiness, increased total sleep time) Opioids: · During intoxication: central sleep apnea, hypoventilation (respiratory depression), sleep fragmentation · During withdrawal: severe insomnia, restlessness Sedatives/Benzodiazepines: · During intoxication: hypersomnia, daytime sedation, increased NREM sleep · During withdrawal: severe insomnia, nightmares, REM rebound (vivid dreams, agitation) Stimulants (amphetamines, methylphenidate): · During intoxication: insomnia, total sleep deprivation · During withdrawal: hypersomnia, excessive sleepiness, increased total sleep time Antidepressants (SSRIs, SNRIs, MAOIs): · Can cause insomnia (activating), excessive sleepiness (sedating), or REM sleep behavior disorder (rare) --- Treatment General principle: The sleep disorder typically resolves with discontinuation of the substance or management of withdrawal. Specific approaches: For insomnia during intoxication: · Reduce or stop the substance · Avoid substituting with another sedative-hypnotic (creates new dependence) For insomnia during withdrawal: · Often severe; may require temporary symptomatic treatment · Benzodiazepines or gabapentin for alcohol withdrawal insomnia · Tapering protocol for sedative withdrawal (slow reduction under medical supervision) For hypersomnia during intoxication: · Eliminate the sedating substance · May require gradual reduction if dependence present For hypersomnia during withdrawal (stimulant withdrawal): · Supportive care, gradual return to normal sleep · No specific medication typically needed Important: Do not diagnose substance/medication-induced sleep disorder if the sleep disturbance pre-dated the substance use. In that case, the substance may be exacerbating a pre-existing sleep disorder, not causing it. --- Prognosis Excellent with: · Removal of causative substance · Appropriate management of withdrawal · No underlying primary sleep disorder Guarded if: · Substance use continues · There is an unrecognized primary sleep disorder (insomnia, sleep apnea, RLS) that led to self-medication with substances Key quote: Always consider substance use in any patient presenting with new-onset insomnia or hypersomnia, especially if the onset is abrupt. --- Final Summary of Key Points for Substance/Medication-Induced Sleep Disorder 1. Sleep disturbance develops within 1 month of substance use or withdrawal 2. Must rule out pre-existing sleep disorder 3. Common causes: alcohol, caffeine, cannabis, opioids, sedatives, stimulants 4. Withdrawal from sedatives and alcohol causes severe insomnia and nightmares 5. Withdrawal from stimulants causes hypersomnia 6. Treatment focuses on eliminating or reducing the causative substance 7. Never prescribe sedatives to treat withdrawal-related insomnia if the withdrawal is from sedatives (will perpetuate the cycle) --- End of Complete DSM-5 Sleep-Wake Disorders Classification This document covers all 10 major sleep-wake disorders as classified in the DSM-5, formatted consistently with the Insomnia Disorder model. Each disorder includes definition, epidemiology, risk factors, pathophysiology, clinical features, DSM-5 criteria, specifiers, differential diagnosis, comorbidity, functional consequences, treatment, prognosis, and a final summary. References: · American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). · Clinical practice guidelines and consensus statements as referenced within individual sections.